A Phase 3 interventional study of PD-1 inhibitor and Capecitabine in Nasopharyngeal Carcinoma (NPC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-04.
Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 140 studies testing Immune checkpoint inhibitors in Nasopharyngeal Carcinoma — 73 open to participants now, 98 under way, 27 of them phase 3. A drug class: Immune checkpoint inhibitors · Nasopharyngeal Carcinoma.
Among the 140 studies testing Immune checkpoint inhibitors in Nasopharyngeal Carcinoma, this one is the 3rd largest by planned enrollment, is one of 12 that started in 2026, is one of 26 in phase 3, reaches primary completion later than 93 of the 97 other live ones, and was the 135th registered.
683 studies on the registry are indexed under Nasopharyngeal Carcinoma; 270 are open to participants now.
Browse Nasopharyngeal Carcinoma studies →73 of the 140 studies testing Immune checkpoint inhibitors in Nasopharyngeal Carcinoma are open now, in 9 countries. Recruiting first, the newest first:
First Affiliated Hospital of Guangxi Medical University · Sites in China
Ages 18–70
Hongmeng Yu · Sites in China
Ages 18–80
Chongqing University Cancer Hospital · Sites in China
Ages 18–65
Sun Yat-sen University · Sites in China
Ages 18–65
MediLink Therapeutics (Suzhou) Co., Ltd. · Sites in China
Ages 18–75
By country, each count listing its studies:
A class of medicines: which ones, and the studies of each, are on its page →
Of the 186 Nasopharyngeal Carcinoma studies recruiting now, 42 (23%) set no upper age limit and 135 (73%) stop at 75 or younger; 9 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
140 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 104 · Phase 3 29
First in 2015; this study’s year is marked. 12 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 651 is above the median of 100 across 557 interventional studies indexed under Nasopharyngeal Carcinoma.
Median enrollment 75 across the 140 interventional studies. Of the 26 that completed or were terminated, 6 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 140 have an industry lead sponsor. The 10 most frequent:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences is the lead sponsor of 396 studies on the registry; 281 are open to participants now.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences has 5 studies filed under Nasopharyngeal Carcinoma — fewer than ten, so there is no comparison to draw.
21 of the studies testing Immune checkpoint inhibitors in Nasopharyngeal Carcinoma that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05340491Phase 3Sun Yat-sen UniversityChemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial | 2026-12 |
| NCT03907826Phase 3Sun Yat-sen UniversityPD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients | 2026-12 |
| NCT06177301Phase 3Fudan UniversityTislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC | 2026-12 |
| NCT06383780Phase 3XIANG YANQUNTislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis. | 2027-05-15 |
| NCT05342792Phase 3Sun Yat-sen UniversityMetronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma | 2027-06 |
Add all 21 to your calendar (.ics) → With an account.
Among the 140 studies testing Immune checkpoint inhibitors in Nasopharyngeal Carcinoma, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate a personalized approach for treating patients with locoregionally advanced nasopharyngeal carcinoma (NPC). Currently, many high-risk patients receive additional treatment (adjuvant therapy) after standard chemoradiotherapy to prevent the cancer from returning. However, some patients may not actually need this extra treatment and could safely avoid its side effects.
This trial uses a novel risk prediction model called the Response-Adapted Individualized Risk Index (RAIRI). The RAIRI model evaluates how a patient's tumor and blood markers (such as Epstein-Barr Virus DNA) respond during and immediately after their initial chemoradiotherapy.
In this study, patients will be randomly assigned to one of two groups:
The main goal of this study is to determine if using the RAIRI model to exempt low-risk patients from adjuvant therapy is as safe and effective as giving adjuvant therapy to everyone, measured by how long patients live without the disease returning or progressing.
Background and Rationale Locoregionally advanced nasopharyngeal carcinoma is commonly treated with definitive intensity-modulated radiotherapy combined with platinum-based chemotherapy, with or without induction therapy. Although modern radiotherapy and systemic treatment have substantially improved disease control, a considerable proportion of patients remain at risk of locoregional recurrence, distant metastasis, or death after standard treatment.
Adjuvant therapy, including metronomic capecitabine or PD-1 inhibitor monotherapy, has been shown to improve failure-free or event-free survival in selected high-risk patients. However, the absolute survival benefit is modest, and many patients may receive unnecessary adjuvant treatment, resulting in additional toxicity, prolonged treatment duration, increased financial burden, and impaired quality of life.
Current adjuvant treatment decisions are mainly based on pretreatment clinical risk factors, such as tumor stage, nodal stage, and baseline plasma Epstein-Barr virus DNA level. These static baseline factors do not fully capture interpatient heterogeneity in treatment response. Increasing evidence suggests that dynamic treatment-response markers, including longitudinal changes in plasma cell-free Epstein-Barr virus DNA and radiographic tumor regression during or after treatment, provide important prognostic information. A response-adapted strategy may therefore allow more precise identification of patients who can safely omit adjuvant treatment and those who may still require additional therapy.
RAIRI Model The response-adapted individualized risk index, or RAIRI, was developed to provide individualized dynamic risk prediction for patients with non-metastatic nasopharyngeal carcinoma. The model incorporates baseline clinical factors, longitudinal plasma cell-free Epstein-Barr virus DNA changes, and imaging-based tumor response assessments collected during treatment.
In prior validation cohorts, RAIRI showed favorable calibration and discrimination for predicting progression-free survival and overall survival. The model also demonstrated potential value for predicting the benefit of adjuvant chemotherapy. Patients categorized as RAIRI low-risk had favorable long-term outcomes and appeared to derive limited benefit from adjuvant capecitabine, whereas RAIRI high-risk patients were more likely to benefit from intensified adjuvant treatment.
Study Objective This trial is designed to prospectively evaluate whether RAIRI-guided adjuvant treatment decision-making can preserve survival outcomes while reducing unnecessary adjuvant therapy in patients with high-risk locoregionally advanced nasopharyngeal carcinoma.
The primary objective is to determine whether a RAIRI-guided adjuvant treatment strategy is non-inferior to standard adjuvant therapy with respect to 3-year failure-free survival. Additional objectives include evaluating the prognostic performance of RAIRI risk stratification and assessing whether observation in RAIRI low-risk patients can safely replace routine adjuvant therapy.
Study Design This is a prospective, multicenter, randomized, open-label, phase III non-inferiority trial. Approximately 651 eligible patients with high-risk locoregionally advanced, non-metastatic nasopharyngeal carcinoma will be enrolled.
Participants will be randomly assigned in a 1:1 ratio to either the experimental arm or the standard-treatment arm. Randomization will be stratified by study center, clinical stage, and use of neoadjuvant treatment.
Study Population Eligible patients will have histologically confirmed Epstein-Barr virus-encoded RNA-positive, non-metastatic, non-keratinizing nasopharyngeal carcinoma. Patients should have high-risk locoregionally advanced disease according to the protocol-defined staging and risk criteria, adequate organ function, Eastern Cooperative Oncology Group performance status of 0 or 1, available baseline plasma Epstein-Barr virus DNA testing, and measurable tumor lesions on baseline magnetic resonance imaging.
Patients with metastatic disease, insufficient baseline data, prior malignancies except selected low-risk cancers, severe uncontrolled comorbidities, active autoimmune disease requiring systemic immunosuppression, active infections requiring systemic treatment, pregnancy or lactation, or inability to comply with follow-up will be excluded.
Standard Treatment Before Adjuvant Therapy All participants will receive standard definitive chemoradiotherapy. Induction chemotherapy or chemoimmunotherapy may be administered before radiotherapy at the discretion of the treating physician based on disease characteristics and patient preference.
Radiotherapy will be delivered using intensity-modulated radiotherapy according to protocol-defined target-volume delineation, dose prescription, and organ-at-risk constraints. Concurrent chemotherapy will be mainly platinum-based. After completion of chemoradiotherapy, patients will undergo response assessment, including plasma cell-free Epstein-Barr virus DNA testing and nasopharyngeal/neck magnetic resonance imaging at protocol-specified time points.
Treatment Arms Experimental Arm: RAIRI-Guided Adjuvant Strategy In the experimental arm, adjuvant therapy will be individualized according to post-chemoradiotherapy RAIRI risk stratification.
Patients classified as RAIRI low-risk, defined as a predicted 5-year progression-free survival of 85% or higher, will not receive adjuvant therapy and will undergo observation and standard follow-up.
Patients classified as RAIRI high-risk, defined as a predicted 5-year progression-free survival of less than 85%, will receive adjuvant therapy with either a PD-1 inhibitor or metronomic capecitabine.
Standard-Treatment Arm In the standard-treatment arm, all patients will receive adjuvant therapy after chemoradiotherapy, regardless of RAIRI risk category. Adjuvant treatment will consist of either PD-1 inhibitor monotherapy or metronomic capecitabine, selected by the treating physician according to clinical circumstances and previous treatment exposure.
Patients receiving PD-1 inhibitor therapy will receive treatment every 3 weeks for up to 12 cycles unless disease progression, unacceptable toxicity, death, or patient refusal occurs. Patients receiving metronomic capecitabine will receive oral capecitabine twice daily for up to 1 year unless unacceptable toxicity, disease progression, withdrawal of consent, or other discontinuation criteria occur.
RAIRI Risk Assessment RAIRI risk stratification will be performed after completion of chemoradiotherapy using baseline clinical characteristics, longitudinal plasma cell-free Epstein-Barr virus DNA dynamics, and imaging-based tumor response assessments. The model will generate an individualized predicted 5-year progression-free survival probability.
A predicted 5-year progression-free survival of 85% or higher will define the RAIRI low-risk group. A predicted 5-year progression-free survival of less than 85% will define the RAIRI high-risk group.
To ensure standardized assessment, RAIRI scoring will be performed according to protocol-specified procedures. Clinical, imaging, and Epstein-Barr virus DNA data will be submitted for centralized review when required. Quality-control procedures will be implemented to ensure consistency across participating centers.
Primary Endpoint The primary endpoint is 3-year failure-free survival, defined as the time from randomization to locoregional recurrence, distant metastasis, or death from any cause, whichever occurs first.
Secondary Endpoints Secondary endpoints include 3-year overall survival, 3-year locoregional relapse-free survival, 3-year distant metastasis-free survival, complete response rate after chemoradiotherapy, the proportion of patients classified as RAIRI low-risk or high-risk after chemoradiotherapy, acute and late toxicities, adverse events, and changes in health-related quality of life.
Toxicities and adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Health-related quality of life will be evaluated using the EORTC QLQ-C30 and head-and-neck cancer-specific instruments at baseline and during follow-up.
Follow-up and Assessments Patients will be followed regularly after treatment. Follow-up assessments will include medical history, physical examination, laboratory tests including plasma Epstein-Barr virus DNA, nasopharyngoscopy, nasopharyngeal and neck imaging, chest imaging, abdominal imaging, and additional examinations when clinically indicated.
Suspected locoregional recurrence or distant metastasis will be confirmed by pathology whenever feasible. When biopsy is not possible, recurrence or metastasis may be diagnosed through multidisciplinary clinical and radiologic assessment.
Statistical Considerations The primary efficacy analysis will be performed in the intention-to-treat population. Failure-free survival and other time-to-event endpoints will be estimated using the Kaplan-Meier method. Treatment groups will be compared using stratified log-rank tests, and hazard ratios with corresponding confidence intervals will be estimated using Cox proportional hazards models.
A hierarchical testing strategy will be used. The first objective is to test whether the RAIRI-guided strategy is non-inferior to standard adjuvant treatment in the overall study population. If this objective is met, the study will further evaluate whether observation in RAIRI low-risk patients in the experimental arm is non-inferior to adjuvant therapy in RAIRI low-risk patients in the standard-treatment arm. The study will also independently assess whether RAIRI can reliably stratify patients into prognostically distinct low-risk and high-risk groups.
Safety analyses will include all patients who receive study treatment. Predefined subgroup analyses will evaluate the consistency of treatment effects across clinically relevant subgroups, including age, sex, Eastern Cooperative Oncology Group performance status, T category, N category, clinical stage, baseline Epstein-Barr virus DNA level, and use of neoadjuvant therapy.
Significance of the Study This study aims to establish a response-adapted precision treatment strategy for locoregionally advanced nasopharyngeal carcinoma. If successful, RAIRI-guided treatment may allow low-risk patients to avoid unnecessary adjuvant therapy while maintaining disease control, and may help identify high-risk patients who require additional treatment after chemoradiotherapy. This approach has the potential to improve individualized treatment decision-making, reduce treatment burden, and optimize the therapeutic value of adjuvant therapy in nasopharyngeal carcinoma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in this arm will receive standard concurrent chemoradiotherapy (CCRT) with or without induction chemotherapy (IC). Following CCRT, all patients will receive standard adjuvant therapy, consisting of either a PD-1 inhibitor (administered intravenously every 3 weeks for up to 12 cycles) or metronomic capecitabine (650mg/m2 orally twice daily for one year), based on the investigator's discretion.
Drug: PD-1 inhibitor · Drug: Capecitabine
Patients will receive standard CCRT with or without IC. After radiotherapy, patients are stratified using the Response-Adapted Individualized Risk Index (RAIRI) model. Patients identified as RAIRI Low-Risk (predicted 5-year PFS ≥ 85%) will be exempted from adjuvant therapy and undergo regular observation. Patients identified as RAIRI High-Risk (predicted 5-year PFS \< 85%) will receive adjuvant therapy (PD-1 inhibitor or capecitabine).
Drug: PD-1 inhibitor · Drug: Capecitabine
Administered intravenously every 3 weeks for up to 12 cycles as adjuvant therapy.
Metronomic capecitabine administered orally at a dose of 650 mg/m2 twice daily for one year as adjuvant therapy.
3-year Failure-Free Survival (FFS)
FFS is defined as the time from randomization to locoregional recurrence, distant metastasis, or death from any cause.
Time frame: Up to 3 years
3-year Overall Survival (OS)
OS is defined as the time from randomization to death from any cause.
Time frame: Up to 3 years
3-year Locoregional Relapse-Free Survival (LRRFS)
LRRFS is defined as the time from randomization to the first locoregional recurrence or death from any cause.
Time frame: Up to 3 years
3-year Distant Metastasis-Free Survival (DMFS)
DMFS is defined as the time from randomization to the first distant metastasis or death from any cause.
Time frame: Up to 3 years
Complete Response (CR) Rate after Chemoradiotherapy
Proportion of patients achieving a complete response after the completion of concurrent chemoradiotherapy.
Time frame: 1 month after the completion of radiotherapy
Incidence of Acute and Late Toxicities and Adverse Events
Adverse events will be evaluated and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.
Time frame: From the start of treatment up to 3 years
Quality of Life (QoL) and its changes
Quality of life and its changes will be assessed using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) version 3.0.
Time frame: From baseline up to 36 months after randomization
Plan to share: Yes — De-identified individual participant data (IPD) that underlie the results reported in the published article will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be available beginning 6 months following article publication.
Access criteria: Data will be shared with researchers whose proposed use of the data has been approved by an independent review committee identified for this purpose. Proposals should be directed to the corresponding author's email.
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Dec 2030, 55 months after the start.
Of 84 phase 3 interventional studies under Nasopharyngeal Carcinoma, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 82. This study's planned 55 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Immune checkpoint inhibitors · Capecitabine
Cancer Institute and Hospital, Chinese Academy of Medical Sciences →